Management of prosthetic joint infections in France : a national audit to identify key situations requiring innovation and homogenization
BACKGROUND: Prosthetic joint infections (PJI) are one of the most serious complication of arthroplasty. The management of PJI needs a multidisciplinary collaboration between orthopaedic surgeon, infectious disease specialist and microbiologist. In France, the management of PJI is organized around reference centres (CRIOACs). Our main objective was to perform an audit through a questionnaire survey based on clinical cases, to evaluate how French physicians manage PJI. Eligible participants were all physicians involved in care of patients presenting a PJI. Physicians could answer individually, or collectively during a multidisciplinary team meeting dedicated to PJI. The survey consisted as three questionnaires organized in a total of six clinical cases.
RESULTS: Answers from the CRIOACs to the three questionnaires were 92, 77, and 53%. Between 32 and 39% of respondents did not administer antibiotic prophylaxis despite positive S. aureus pre-operative documentation. One-stage exchange strategy was widely preferred in all clinical cases, with no difference between CRIOACs and other centres. Rifampicin was prescribed for S. aureus PJI, in a situation with (90-92%) or without any prosthesis (70%). There was no consensus for the total antibiotic regimen duration, with prescriptions from six to 12 weeks for a majority of respondents.
CONCLUSIONS: Surgical strategy for the management of PJI was homogenous with a preference for a one-stage exchange strategy. Medical management was more heterogenous, which reflects the heterogeneity of those infections and difficulties to perform studies with strong conclusions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
BMC infectious diseases - 21(2021), 1 vom: 01. Mai, Seite 401 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Le Maréchal, Marion [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 11.05.2021 Date Revised 01.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12879-021-06075-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324861397 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324861397 | ||
| 003 | DE-627 | ||
| 005 | 20240401232141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12879-021-06075-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM324861397 | ||
| 035 | |a (NLM)33933020 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Le Maréchal, Marion |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of prosthetic joint infections in France |b a national audit to identify key situations requiring innovation and homogenization |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.05.2021 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Prosthetic joint infections (PJI) are one of the most serious complication of arthroplasty. The management of PJI needs a multidisciplinary collaboration between orthopaedic surgeon, infectious disease specialist and microbiologist. In France, the management of PJI is organized around reference centres (CRIOACs). Our main objective was to perform an audit through a questionnaire survey based on clinical cases, to evaluate how French physicians manage PJI. Eligible participants were all physicians involved in care of patients presenting a PJI. Physicians could answer individually, or collectively during a multidisciplinary team meeting dedicated to PJI. The survey consisted as three questionnaires organized in a total of six clinical cases | ||
| 520 | |a RESULTS: Answers from the CRIOACs to the three questionnaires were 92, 77, and 53%. Between 32 and 39% of respondents did not administer antibiotic prophylaxis despite positive S. aureus pre-operative documentation. One-stage exchange strategy was widely preferred in all clinical cases, with no difference between CRIOACs and other centres. Rifampicin was prescribed for S. aureus PJI, in a situation with (90-92%) or without any prosthesis (70%). There was no consensus for the total antibiotic regimen duration, with prescriptions from six to 12 weeks for a majority of respondents | ||
| 520 | |a CONCLUSIONS: Surgical strategy for the management of PJI was homogenous with a preference for a one-stage exchange strategy. Medical management was more heterogenous, which reflects the heterogeneity of those infections and difficulties to perform studies with strong conclusions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Arthritis infection | |
| 650 | 4 | |a Clinical audit | |
| 650 | 4 | |a Joint prosthesis | |
| 650 | 4 | |a Rifampin | |
| 650 | 4 | |a Staphylococcus aureus | |
| 650 | 4 | |a Surveys and questionnaires | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Rifampin |2 NLM | |
| 650 | 7 | |a VJT6J7R4TR |2 NLM | |
| 700 | 1 | |a Cavalli, Zoé |e verfasserin |4 aut | |
| 700 | 1 | |a Batailler, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez, Jean-François |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, André |e verfasserin |4 aut | |
| 700 | 1 | |a Lustig, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Ferry, Tristan |e verfasserin |4 aut | |
| 700 | 1 | |a Courjon, Johan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC infectious diseases |d 2001 |g 21(2021), 1 vom: 01. Mai, Seite 401 |w (DE-627)NLM11120089X |x 1471-2334 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:1 |g day:01 |g month:05 |g pages:401 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12879-021-06075-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 1 |b 01 |c 05 |h 401 | ||